Who are Placebo to Mepolizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EXDENSUR, Asthma therapies, anti IL5 receptor antibodies, Mepolizumab Injection [Nucala], Benralizumab Prefilled Syringe, Fasenra®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-mepolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo to Mepolizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Mepolizumab (Placebo to Mepolizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-5 inhibitor. Area: Immunology.

phase 3 IL-5 inhibitor IL-5 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Placebo to Mepolizumab (Placebo to Mepolizumab) — AstraZeneca. Mepolizumab is an interleukin-5 (IL-5) inhibitor that blocks the action of IL-5, a cytokine involved in the production and survival of eosinophils.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Mepolizumab TARGET	Placebo to Mepolizumab	AstraZeneca	phase 3	IL-5 inhibitor	IL-5
EXDENSUR	DEPEMOKIMAB-ULAA	GLAXOSMITHKLINE LLC	marketed		IL-5
Asthma therapies	Asthma therapies	Genentech, Inc.	marketed	Monoclonal antibodies (multiple agents with different targets)	IgE, IL-5, IL-4 receptor alpha (varies by specific agent)
anti IL5 receptor antibodies	anti IL5 receptor antibodies	Scarlata, Simone, M.D.	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor (IL-5R)
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Benralizumab Prefilled Syringe	Benralizumab Prefilled Syringe	Nantes University Hospital	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-5 inhibitor class)

AstraZeneca · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Mepolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-mepolizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab